Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent
Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent
复制标题
DOI：
10.1089/152702902753639522
复制
发表时间：
2002-03-01
影响因子：
2.1
通讯作者：
Onopa, J
中科院分区：
文献类型：
--
作者：
Gertsch, JH;Seto, TB;Onopa, J
先前的研究表明，5天的预防性银杏可以减少渐进式上升过程中的急性高山病(AMS)的发生率。这项试验旨在确定如果在快速上升前1天开始，银杏是否是一种有效的预防性药物。在这项双盲、随机、安慰剂对照试验中，26名居住在海平面上的参与者在攀登夏威夷莫纳克亚之前24小时开始服用银杏(60毫克TID)或安慰剂。受试者从海平面(4205m)被运送到山顶超过3小时，包括在2835m的海拔1小时。路易斯湖自我报告问卷构成了基线(2835m)和4205m的4h后的主要结果测量。AMS被定义为路易斯湖自我报告评分(LLSR)大于或等于3的头痛。在剩下的研究中，患上严重急性呼吸综合征的受试者立即被转移到较低的海拔地区。银杏组(n=12)和安慰剂组(n=14)匹配良好(58%对50%女性；中位年龄28岁，范围22-53对33岁，范围21-53；58%对57%高加索人)。2名服用银杏的受试者(17%)和9名服用安慰剂的受试者(%)发展为严重的急性呼吸窘迫综合征，为了他们的安全需要下降(p=0.021)；所有人都痊愈了，没有后遗症。银杏组在4205米处的LLSR中位数显著低于安慰剂组(4，范围1-8对5，范围2-9，p=0.03)。与安慰剂相比，银杏的使用在降低AMS发生率方面没有达到统计学意义(银杏7/12，58.3%对安慰剂13/14，92.9%，p=0.07)。26名受试者中有21名(81%)总体上发展为AMS。这是第一项研究表明，银杏60 mg TID预处理1天可以显著降低AMS从海平面快速上升到4205米之前的严重程度。
Previous studies suggest that 5 days of prophylactic ginkgo decreases the incidence of acute mountain sickness (AMS) during gradual ascent. This trial was designed to determine if ginkgo is an effective prophylactic agent if begun 1 day prior to rapid ascent. In this double-blind, randomized, placebo-controlled trial, 26 participants residing at sea level received ginkgo (60 mg TID) or placebo starting 24 h before ascending Mauna Kea, Hawaii. Subjects were transported from sea level to the summit (4205 m) over 3 hours, including I hour at 2835 m. The Lake Louise Self-report Questionnaire constituted the primary outcome measure at baseline, 2835 m, and after 4 h at 4205 m. AMS was defined as a Lake Louise Self-report Score (LLSR) greater than or equal to 3 with headache. Subjects who developed severe AMS were promptly transported to lower altitude for the remainder of the study. The ginkgo (n = 12) and placebo (n = 14) groups were well matched (58% vs. 50% female; median age 28 yr, range 22-53 vs. 33 yr, range 21-53; 58% vs. 57% Caucasian). Two (17%) subjects on ginkgo and nine (64%) on placebo developed severe AMS and required descent for their safety (p = 0.021); all recovered without sequelae. Median LLSR at 4205 m was significantly lower for ginkgo versus placebo (4, range 1-8 vs. 5, range 2-9, p = 0.03). Ginkgo use did not reach statistical significance for lowering incidence of AMS compared with placebo (ginkgo 7/12, 58.3% vs. placebo 13/14, 92.9%, p = 0.07). Twenty-one of 26 (81%) subjects developed AMS overall. This is the first study to demonstrate that 1 day of pretreatment with ginkgo 60 mg TID may significantly reduce the severity of AMS prior to rapid ascent from sea level to 4205 m.